Professor Hiroshi Ito of Keio University School of Medicine announced that he will start clinical research to administer "nicotinamide mononucleotide (NMN)", which is expected as an aging regulator, to humans for the first time in the world. Professor Shinichiro Imai of the University of Washington School of Medicine, who discovered NMN, will also cooperate in formulating research implementation plans.
The research group has made various attempts to prevent diseases that increase with age, with an eye on an aging society.Recent studies have revealed that the substance "nicotinamide adenine dinucleotide (NAD)" that is naturally present in the body decreases in various organs with aging, resulting in diseases such as diabetes. NAD is known to activate a molecule called "sirtuin" that is associated with longevity.One of the materials for making this NAD in the body is NMN, which is a type of vitamin B3.However, the details of how NMN affects various organs were unknown.
The research group is conducting clinical research with the aim of investigating the safety of NMN when administered to humans and the pharmacokinetics of how NMN is absorbed in the human body and converted to NAD and the like. It was decided to start.The study included 40 healthy men between the ages of 60 and 10.During the study period, different doses of NMN will be given to the same subject, and changes in physiological and blood tests will be used to investigate the safety and pharmacokinetics of NMN administration.
If this clinical study yields results on the safety and pharmacokinetics of NMN, we will move toward the realization of a nutritional approach for the treatment and prevention of evidence-based age-related diseases. It is expected to develop into clinical research.This time, it will be conducted as a clinical study aimed at obtaining academic knowledge, not as a clinical trial for drug development.
